Anticoagulant Treatment in COVID-19: a Narrative Review

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2020 Aug 19

PMID 32809158

Citations 47

Authors

Vincenzo Carfora

Giorgio Spiniello

Riccardo Ricciolino

Marco Di Mauro

Marco Giuseppe Migliaccio

Filiberto Fausto Mottola

Nicoletta Verde

Nicola Coppola

Affiliations

Soon will be listed here.

Abstract

The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels. Thrombotic risk seems to be directly related to disease severity and worsens patients' prognosis. Therefore, the correct understanding of the mechanisms underlying COVID-19 induced prothrombotic state can lead to a thorough assessment of the possible management strategies. Hence, we review the pathogenesis and therapy of COVID 19-related thrombosis disease, focusing on the available evidence on the possible treatment strategies and proposing an algorithm for the anticoagulation strategy based on disease severity.

Citing Articles

Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.

Velasquez P, Hernandez J, Galeano E, Hincapie-Garcia J, Rugeles M, Zapata-Builes W Clin Pharmacol. 2024; 16:1-25.

PMID: 38197085 PMC: 10773251. DOI: 10.2147/CPAA.S429064.

Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence.

Ragnoli B, Da Re B, Galantino A, Kette S, Salotti A, Malerba M Int J Mol Sci. 2023; 24(10).

PMID: 37240292 PMC: 10219009. DOI: 10.3390/ijms24108945.

IL1RA mediated the effects of aspirin on COVID-19 severity: A Mendelian randomization study.

Liu X, Lv Z, Wang Q, Yu J, Wang J, Zhou Y J Infect. 2023; 86(4):410-411.

PMID: 36690213 PMC: 9852317. DOI: 10.1016/j.jinf.2023.01.025.

A snake venom-analog peptide that inhibits SARS-CoV-2 and papain-like protease displays antithrombotic activity in mice arterial thrombosis model, without interfering with bleeding time.

Nogueira R, Salu B, Nardelli V, Bonturi C, Pereira M, Maffei F Thromb J. 2023; 21(1):1.

PMID: 36593467 PMC: 9806807. DOI: 10.1186/s12959-022-00436-5.

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal....

Aston D, Besser M, Goddard B, Maggs N, Ahmed H, Falter F Clin Appl Thromb Hemost. 2022; 28:10760296221148162.

PMID: 36572963 PMC: 9806398. DOI: 10.1177/10760296221148162.

References

Self W, Semler M, Leither L, Casey J, Angus D, Brower R . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21):2165-2176. PMC: 7653542. DOI: 10.1001/jama.2020.22240. View

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

Li R, Pei S, Chen B, Song Y, Zhang T, Yang W . Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020; 368(6490):489-493. PMC: 7164387. DOI: 10.1126/science.abb3221. View

Sardu C, DOnofrio N, Balestrieri M, Barbieri M, Rizzo M, Messina V . Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?. Diabetes Care. 2020; 43(7):1408-1415. PMC: 7305003. DOI: 10.2337/dc20-0723. View

Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M . Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19. Circulation. 2020; 142(19):1881-1884. PMC: 7643783. DOI: 10.1161/CIRCULATIONAHA.120.050907. View

Wang J, Li Y . Testing Clinical Prediction Models. JAMA. 2020; 324(19):1999-2000. DOI: 10.1001/jama.2020.19389. View

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

Bikdeli B, Madhavan M, Gupta A, Jimenez D, Burton J, Nigoghossian C . Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020; 120(7):1004-1024. PMC: 7516364. DOI: 10.1055/s-0040-1713152. View

10.

Lee M, Brooksbank K, Wetherall K, Mangion K, Roditi G, Campbell R . Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. 2020; 143(6):516-525. PMC: 7864599. DOI: 10.1161/CIRCULATIONAHA.120.052186. View

11.

Merle N, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina L . Complement System Part II: Role in Immunity. Front Immunol. 2015; 6:257. PMC: 4443744. DOI: 10.3389/fimmu.2015.00257. View

12.

Schouten M, Wiersinga W, Levi M, van der Poll T . Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2007; 83(3):536-45. DOI: 10.1189/jlb.0607373. View

13.

Boger R, Hannemann J . Dual role of the L-arginine-ADMA-NO pathway in systemic hypoxic vasodilation and pulmonary hypoxic vasoconstriction. Pulm Circ. 2020; 10(2):2045894020918850. PMC: 7153195. DOI: 10.1177/2045894020918850. View

14.

Dashti-Khavidaki S, Khalili H . Considerations for Statin Therapy in Patients with COVID-19. Pharmacotherapy. 2020; 40(5):484-486. PMC: 7262253. DOI: 10.1002/phar.2397. View

15.

Marinella M . Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int J Clin Pract. 2020; 74(9):e13535. PMC: 7261995. DOI: 10.1111/ijcp.13535. View

16.

Zermeno A . The nuclear magnetic resonance phenomenon: an introduction. Curr Probl Cancer. 1982; 7(3):4-19. DOI: 10.1016/s0147-0272(82)80006-8. View

17.

Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kroller-Schon S . New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. Int J Mol Sci. 2019; 20(1). PMC: 6337296. DOI: 10.3390/ijms20010187. View

18.

Scavone M, Rizzo J, Femia E, Podda G, Bossi E, Caberlon S . Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin. Thromb Haemost. 2020; 120(10):1442-1453. DOI: 10.1055/s-0040-1714351. View

19.

Xu X, Han M, Li T, Sun W, Wang D, Fu B . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975. PMC: 7245089. DOI: 10.1073/pnas.2005615117. View

20.

Diurno F, Numis F, Porta G, Cirillo F, Maddaluno S, Ragozzino A . Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020; 24(7):4040-4047. DOI: 10.26355/eurrev_202004_20875. View

21.

Gerotziafas G, Catalano M, Colgan M, Pecsvarady Z, Wautrecht J, Fazeli B . Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost. 2020; 120(12):1597-1628. PMC: 7869052. DOI: 10.1055/s-0040-1715798. View